New drug litfulo tracked in Real-World hair loss study

This study monitors the long-term safety and effectiveness of the drug Litfulo (ritlecitinib) in 487 patients with alopecia areata, a condition causing patchy hair loss. Researchers will track side effects and measure hair regrowth using the SALT score, aiming for a score of 20 or less (meaning minimal scalp hair loss). The study follows patients in real-world settings, not a controlled lab.